hVIVO has announced its scheduled 1H25 trading update, highlighting revenues for the period of £24.2m (1H24: £35.6m) in line with our existing expectations for full-year revenues of £47m. While macro and sector-specific headwinds including the subdued biotech funding environment have impacted the broader CRO industry – with delayed contract conversion and a number of cancellations and postponements – the company’s weighted contracted order book at period-end was £40m and the aggregate value of c ....
